AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/00002
Drug name and formulations:	Fluticasone Furoate (Avamys®)

Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	The APC considered that the clinical data presented indicated that the product is associated with low risk of harm.
Clinical effectiveness	*Established licensed product*	The APC noted evidence that fluticasone furoate was non inferior to fluticasone propionate and comparable to mometasone furoate in reducing symptoms of rhinitis. It is licensed for use in adults and children aged 6 years and over. Fluticasone furoate is supplied in a device using a side button for actuation which may be more convenient for patients. It has a lower volume per spray than mometasone and fluticasone propionate which may lead to less drip down the throat.
Strength of evidence		Moderate— randomised, double-blind placebo-controlled, parallel-group studies
Cost effectiveness or resource impact	*£*	The APC noted that the current first line treatment option, beclometasone dipropionate, is a more cost effective alternative and can be purchased OTC for less than £4.00. However, Avamys® is of similar costs to the fluticasone proprionate (Nasofan®) preparation and mometasone (Nasonex®) spray, and £1 cheaper than Flixonase®.
Place of therapy relative to available treatments	*1/2nd tier*	Second tier
National guidance and priorities	*NICE, MTRAC*	Scottish Medicines Consortium. fluticasone furoate (Avamys®) SMC Advice. SMC ID No. 544/09.

		Fluticasone furoate (Avamys®) is accepted for use within NHS Scotland for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and over) and children (6 to 11 years). Evidence to support its efficacy comes from a number of comparator- and placebo-controlled studies conducted in adults and children with seasonal and perennial allergic rhinitis.
Local health priorities	*CCG views*	Low commissioning priority
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A – not innovative
Implementation requirements	*Requires, RICAD ESCA etc.*	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN: can be used as second line to beclometasone (joint second line agent with mometasone spray) The APC noted the comments around cost effectiveness/pricing and ease of use, indication for children.
Implementation requirements:	N/A
Implementation monitoring:	N/A

References

- Summary of Product Characteristics www.medicines.org.uk Fluticasone furoate, 27.5 micrograms/actuation nasal spray (Avamys®).
- Scottish Medicines Consortium assessment 06 march 2009. SMC ID No. 544/09. https://www.scottishmedicines.org.uk/Press_Statements/544_09_fluticasone_furoate__Avamys®_
- UKMI New Medicines Profile -Fluticasone furoate nasal spray.. Issue No. 09/03. May 2009. http://www.medicinesresources.nhs.uk/upload/documents/Evidence/Drug%20Specific%20Reviews/NMPAvamysMay09.pdf
- Scadding GK et al. BSACI (British Society for Allergy and clinical Immunology) guidelines for the management of allergic and non-allergic rhiniti. Clinical and Experimental Allergy, 2008; 38: 19-42